|
Patent landscape, scope, and claims summary: |
United States Patent 10,632,112: HBV Treatment Using a Capsid Assembly Inhibitor Plus Pegylated Interferon
What does US 10,632,112 claim, in operational terms?
US 10,632,112 claims treatment of hepatitis B virus (HBV) infection by administering (i) a “capsid assembly inhibitor” defined by a broad Formula I chemical genus and (ii) pegylated interferon. The core patent protection is not limited to a specific drug candidate; it is drafted as a genus-method and composition-method covering a wide range of Formula I analogs when combined with pegylated interferons and in multiple dosing formats.
Claim 1 (method claim): treatment plus capsid inhibitor genus + pegylated interferon
Claim 1 requires:
- Indication: “treating an HBV infection”
- Dosage concept: administering a capsid assembly inhibitor and pegylated interferon
- Capsid assembly inhibitor identity: “compound of Formula I” (or salt)
- Pegylated interferon: not defined in claim 1, but narrowed in dependent claims
Claim 1 is defined by an expansive set of substituent and linkage variables:
- R4 = H or C1-C6 alkyl
- R5: broad functional class set including halogens, cyano (–CN), nitro (–NO2), multiple thio/oxo-thio motifs (via “(L)m-S…”, “(L)m-S(O)…” and “(L)m-S(O)2…”), sulfonamide-like motifs (via “(L)m-NH(SO2)…”, etc.), and carbonyl/ester/amides motifs (via “(L)mCO2…” and “(L)mOCO2…”, “(L)mN(R8)2…”, “(L)mC(OH)(R8)2…” and “(L)mC(NH2)(R8)2…”). Also includes haloalkyl/dihaloalkyl/trihaloalkyl.
- L: bivalent radical comprising alkylene, cycloalkylene, or substituted alkylene-ether/alkylene-amino linkers
- R8: very broad, including H, alkyl, haloalkyl/dihalo/trihaloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and alkyl-aryl/alkyl-heteroaryl combinations
- R9: similarly broad substituent family
- R10: includes OH, alkyl, haloalkyl/dihalo/trihaloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and alkyl-aryl/alkyl-heteroaryl
- R11: bond or C1-C3 alkylene with optional substitution
- R2: includes OH, halo, –CN, –NO2, alkyl, alkoxy, haloalkyl/dihalo/trihaloalkyl, heteroalkyl, and acyl (C(O)–C1-C6 alkyl)
- Stereochemical/positional variables: w = 0,1,2; x = 0-4; y = 1-3; z = 0-3; m = 0-2
Practical effect: Claim 1 covers a “capsid assembly inhibitor” genus paired with pegylated interferon for HBV.
Claim 2-4 (pegylated interferon narrowing)
Dependent claims narrow the interferon list to specific pegylated interferon products:
- Claim 2: pegylated interferon among:
- peginterferon-alpha 2a
- peginterferon alpha-2b
- peginterferon beta-1a
- peginterferon lambda-1
- DA-3021
- PEG-Infergen
- Claim 3: subset: peginterferon alpha-2a, alpha-2b, alpha-1a, and lambda-1
- Claim 4: peginterferon alpha-2a specifically
Claims 5-13 (formulation and timing variants)
The patent anticipates multiple product-delivery strategies:
- Claim 5: pegylated interferon and Formula I compound in single formulation or unit dosage form
- Claim 6: includes pharmaceutically acceptable carrier
- Claim 7: administered separately
- Claims 9-13: timing patterns and separate formulations:
- Claim 9: administer at substantially the same time
- Claim 10: administer at different times
- Claim 11: pegylated interferon first, then capsid inhibitor
- Claim 12: capsid inhibitor first, then pegylated interferon
- Claim 13: separate formulations or unit dosage forms
Claim 14 (combination effectiveness framing)
Claim 14 requires a specific combination rationale:
- dosages are “not effective when one or both… are administered alone”
- but are “effective in combination”
This claim element is important because it can shift validity and enforcement toward:
- combination synergy or at least non-obviousness in treatment outcome
- and away from mere additive co-administration
Claim 15-16 (composition and composition method)
- Claim 15: a composition comprising pegylated interferon + Formula I capsid inhibitor
- Claim 16: method of treating HBV by administering the claim 15 composition
Bottom line: the patent covers both method-of-use and composition angles, with broad chemical genus coverage for Formula I and broad interferon product coverage via dependent claim narrowing.
How broad is the chemical genus in Formula I, and what does that do to enforceability?
The Formula I variables make the covered chemical space extremely wide:
- Multiplicity: the claim includes several independently varying substituents across aromatic and linker motifs (R5, R8, R9, R10, R11, and R2 substitution counts).
- Optional substitution counts:
- x ∈ {0,1,2,3,4}
- y ∈ {1,2,3}
- z ∈ {0,1,2,3}
- m ∈ {0,1,2}
- w ∈ {0,1,2}
Even without the full structural drawing of Formula I in the provided text, the combinatorics implied by:
- multiple aromatic substitution positions
- multiple linker possibilities (L)
- and multi-category side chains (including sulfinyl/sulfonyl-like and carbonyl motifs)
creates a genus claim that can span many analogs.
Enforcement pressure point
A broad genus claim typically faces enforceability risk where:
- the genus is not supported by enabling disclosure across the full range
- or prior art teaches the combination generally but not with the exact claimed genus
- or later narrowing requires claim construction toward only a small subset actually enabled
Claim drafting here attempts to reduce the odds of “too broad” rejection by using standard medicinal chemistry variable frameworks (R groups, substituent sets, and alkyl range definitions), but the real enforceability question becomes whether US 10,632,112’s specification supports the full breadth of Formula I.
What is the business-relevant combination claim strategy?
Combination claim is the leverage
The strongest economic hook is not “capsid assembly inhibitors exist” or “interferon exists.” It is the pairing:
- capsid assembly inhibitor of Formula I + pegylated interferon for HBV
plus multiple administration formats:
- single formulation or separate formulations
- same time or different time
- either order of administration
Claim 14 tightens the novelty story
Claim 14 does two things:
- It frames the combination as non-effective alone for the combination dosages.
- It potentially shifts the patent to cover a dosing regimen with combination-specific efficacy.
Dependent interferon coverage
Pegylated interferon is a known HBV therapy class. By explicitly listing interferon types (alpha-2a, alpha-2b, alpha-1a, lambda-1, beta-1a, DA-3021, PEG-Infergen), the patent can:
- capture product-by-product variations in infringement analysis
- and avoid a “generic interferon class” limitation that would be harder to prove infringement against a specific formulation.
Where does this patent likely sit in the HBV patent landscape?
US 10,632,112 is positioned at the intersection of:
- HBV capsid assembly inhibitors (a mechanistic class targeting nucleocapsid assembly)
- pegylated interferons (immune-modulating therapies)
- combination regimens (sequenced, co-formulated, and dose-framed)
Landscape implication
In enforcement, this patent’s novelty likely depends on one or more of:
- the specific Formula I capsid assembly inhibitor genus
- the specific combination with pegylated interferons for HBV
- the dosing/regimen framing in claim 14
- the formulation/timing variants that reduce design-around opportunities
Competitive design-around surfaces
Potential competitors can attempt to avoid infringement by:
- using a different capsid assembly inhibitor scaffold not falling within Formula I
- choosing an interferon not captured by claims 2-4 (though claim 1 is not limited, dependent claims narrow; the infringement analysis depends on claim 1 construction)
- avoiding the dosing regimen framed in claim 14 (requires proving “not effective alone” for those dosages)
- avoiding unit-dose or formulation combinations if only claim 15 is asserted, though claim 1 remains a method-of-use
What claims are most likely to drive litigation risk?
Tier 1: Claim 1 (genus method of treating HBV)
Claim 1 is the broadest and most central. If asserted, it captures:
- any pegylated interferon co-administered with any Formula I compound that meets the genus definition
- any administration format described only in dependent claims if those limitations are inherited via dependent-claim assertion strategy
Tier 2: Claim 14 (combination-only effectiveness at the claimed dosages)
Claim 14 is often litigated because it can be:
- a differentiator versus prior art combination therapy
- a vulnerable element if prior art shows comparable efficacy or if combination effects are known
Tier 3: Claim 15 (composition)
Composition claims are enforceable against product formulation and manufacturing. If competitors sell fixed-dose combinations or co-packaged products that meet claim 15’s definition, they face direct exposure.
Critical claim construction questions that determine validity and infringement
The patent’s drafting creates several construction-critical domains:
-
Capsid assembly inhibitor classification
- Claim 1 does not name a mechanism detail; it labels the compounds as “capsid assembly inhibitors.”
- In practice, infringement can hinge on whether the administered compound is within Formula I and is capable of capsid assembly inhibition in HBV.
-
Formula I boundary
- The variables define inclusion, but claim interpretation must determine:
- whether a candidate compound falls within each substituent definition set
- whether “optionally substituted” counts and position ranges constrain inclusion
-
Pegylated interferon scope
- Claim 1 is broader than dependent claims.
- Dependent claims 2-4 enumerate specific products; if only those are litigated, competitors may seek to use a pegylated interferon outside that enumerated set. If claim 1 is asserted alone, competitors face a wider pegylated interferon capture.
-
Combination regimen element (claim 14)
- Requires a dosage-based effectiveness narrative.
- If prior art supports that pegylated interferon or capsid inhibitors alone provide measurable efficacy at comparable dose levels, claim 14 may be attacked.
-
Timing/order
- Dependent claims 9-13 are designed to cover sequencing.
- Competitors typically cannot avoid infringement just by changing order because at least one dependent path can still capture the regimen unless the asserted claim is limited narrowly to one specific dependency.
Key “landscape” implications for investors and R&D strategists
Combination therapy is the center of gravity
US 10,632,112 is not only a chemical-genus patent; it is a regimen patent with multiple operational vectors:
- co-formulation vs separate administration
- same-time vs sequential
- order-swapping
- combination dose non-effectiveness alone framing
That structure increases the probability of meaningful coverage against real-world clinical use patterns.
Chemical-genus breadth increases coverage but raises enablement risk
From a portfolio perspective, broad genus coverage can:
- make infringement mapping easier for a wide range of analogs
- but also make validity challenges more likely on enablement and written description across the full genus, depending on the specification depth.
Design-around is more about scaffold than administration
Because the patent covers:
- administration order
- timing
- formulation formats
competitors’ most viable design-around typically becomes:
- choose a capsid assembly inhibitor scaffold that is not within Formula I
- or use a capsid inhibitor with defining features that land outside the R-group constraints
Key Takeaways
- US 10,632,112 claims HBV treatment using a capsid assembly inhibitor of Formula I plus pegylated interferon, with coverage expanded through formulation and sequencing variants.
- Claim 1 is the primary breadth anchor: it uses an extensive Formula I genus and does not restrict the interferon type at the independent-claim level.
- Dependent claims 2-4 enumerate pegylated interferon products, narrowing the interferon scope for downstream enforcement arguments.
- Claims 9-13 are drafted to cover practical clinic administration patterns, including same-time vs sequential and both dosing orders.
- Claim 14 is the key differentiation lever: it ties patentability and enforceability to combination dosages that are not effective when given alone.
- For competitive strategy, the most credible design-around lever is likely changing the capsid inhibitor scaffold rather than changing dosing format or sequence.
FAQs
-
Is US 10,632,112 limited to one specific pegylated interferon?
No. Claim 1 broadly covers pegylated interferon; specific products are enumerated in dependent claims (e.g., peginterferon alpha-2a).
-
What is the strongest novelty hook in the claims?
The pairing of a Formula I capsid assembly inhibitor with pegylated interferon for HBV, reinforced by claim 14’s combination-only effectiveness framing at the claimed dosages.
-
Does the patent cover both fixed-dose and separate dosing?
Yes. It includes single formulation/unit dosage forms (claim 5) and separate administration (claims 7 and 13), plus same-time (claim 9) and sequential regimens (claims 10-12).
-
Which claims are most likely to be asserted in enforcement?
Typically claim 1 for broad method coverage, supplemented by claim 14 (dosing effectiveness rationale) and claim 15 (composition), depending on how accused products are marketed and used.
-
Where can competitors most effectively reduce infringement risk?
By using a capsid assembly inhibitor that does not fall within Formula I’s defined R-group and structural variable boundaries, since administration timing and order are already covered across dependent claims.
References
[1] United States Patent 10,632,112. (n.d.). Methods and compositions for treating HBV infection using capsid assembly inhibitors and pegylated interferon.
More… ↓
⤷ Start Trial
|
